Leukemia

After an blood cancer diagnosis and stem cell transplant, I found purpose in crochet, turning fear into creativity and connection one stitch at a time.

Facing leukemia and uncertainty, I leaned on love and resolve to keep living day by day, despite fear and an unknown future ahead.

I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the uncertainty that still lingers.

I celebrated five years since my bone marrow transplant with a surprise video from my donor, a beautiful reminder of the life she helped me keep.

The FDA has granted priority review to an application for Revuforj for the treatment of relapsed or refractory mutant NPM1 acute myeloid leukemia.

I’ve lived with large granular lymphocytic leukemia for 16 years and have learned to spend my energy wisely, embrace palliative care and choose joy over anger.

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.

Nutrition is a challenge for many patients with cancer.

Cancer is one of the most expensive medical conditions to treat in the U.S.

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous leukemia.

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

Patients with lymphoma or leukemia with methotrexate-induced acute kidney injury experienced improved renal outcomes following glucarpidase treatment.

As a cancer treatment waiting room volunteer, I’ve discovered a unique community of shared experiences and unexpected connections.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.

Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.